November 2007 Br J Cardiol 2007;14:255-9
BJCardio editorial team
Prasugrel lowers events but increases bleeding compared with clopidogrel in PCI patients The new antiplatelet agent, prasugrel, reduced ischaemic events compared with clopidogrel but at the cost of an increase in major bleeding in the TRITON-TIMI 38 trial in acute coronary syndrome (ACS) patients scheduled for percutaneous coronary intervention (PCI). Overall mortality did not differ significantly between the two groups. In the study, which has also been published in the New England Journal of Medicine, prasugrel prevented 23 myocardial infarctions (MIs) for every 1,000 patients treated but caused an excess of six non-CABG (coronary artery by
September 2003 Br J Cardiol 2003;10:373-8
Colin Berry, Alan Rae, Jaqueline Taylor, Adrian J Brady
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits